This study specifically addresses individuals with a confirmed genetic predisposition to cancer—namely, carriers of germline P/LP variants in cancer-associated genes such as BRCA1, BRCA2, CHEK2, PALB2, ATM, STK11, and TP53. It does not include individuals with a strong family history but without an identified germline mutation. This evidence concerns the gene CHEK2 and cancer.